A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation
Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers. Background: PBT434 is a novel, small molecule inhibitor of alpha-synuclein aggregation. In…Rapamycin for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Patient Perspective in Multiple System Atrophy
Objective: To report patient and/ or caregiver perspective in Multiple System Atrophy (MSA). Background: The majority of literature on MSA’s natural history comes from single…Is safinamide useful for atypical Parkinsonian syndromes?
Objective: Seeking new treatment strategies in atypical Parkinsonian syndromes Background: Atypical parkinsonian syndromes (APS) include several entities leading to parkinsonism with atypical features such as…The role of deep brain stimulation targeting GPi in patients with multiple system atrophy
Objective: To report clinical outcomes of two patients diagnosed with MSA-P who underwent bilateral deep brain stimulation (DBS). Background: The role of DBS in patients…PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy
Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…Effects of multi-session repetitive transcranial magnetic stimulation on performance of motor control and dynamics of spontaneous brain activity in multiple system atrophy
Objective: To explore the effectiveness of repetitive transcranial magnetic stimulation (rTMS) on performance of motor control and dynamics of spontaneous brain activity in multiple system…Caregiver Burden in a Multidisciplinary MSA Clinic
Objective: To explore the correlation between disease and caregiver burden in MSA. Background: For patients with Multiple System Atrophy (MSA), the increasing loss of independence…Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure
Objective: TD-9855 is a novel NET inhibitor (1) being studied for the treatment of symptomatic nOH. The objective of the present study was to characterize…Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial
Objective: Phase I study with AFFITOPE® PD01A and PD03A to assess safety and tolerability as well as immunogenicity of this approach in MSA patients. Background:…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »